Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications 2014

Adwan H., Murtaja A., Kadhim K., Pervaiz A., Hielscher T., Berger M.R.:  Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biol.Therap. 15 (9) 1185-1197, 2014.

Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., Fenchel M., Eder M., Eisenhut M., Hadaschik B.A., Kopp-Schneider A., Röthke M.:  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur.J.Nucl.Med.Mol.Imag. 41 (5) 887-897, 2014.

Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., Holland-Letz T., Hadaschik B.A., Giesel F.L., Debus J., Haberkorn U.:  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur.J.Nucl.Med.Mol.Imag. 41 11-20, 2014.

Al-Taee K.K., Ansari S., Hielscher T., Berger M.R., Adwan H.:  Metastasis-related processes show various degrees of activation in different stages of pancreatic cancer rat liver metastasis. Oncol.Res.Treat. 37 (9) 464-470, 2014.

Bacelli I., Stenzinger A., Vogel V., Pfitzner B.M., Klein C., Wallwiener M., Scharpff M., Saini M., Holland-Letz T., Sinn H.P., Schneeweiss A., Denkert C., Weichert W., Trumpp A.:  Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 5 (18) 8147-8160, 2014.

Benner A., Mansouri L., Rossi D., Majid A., Willander K., Parker A., Bond G., Pavlova S., Nückel H., Merkel O., Ghia P., Montserrat E., Kaderi M.A., Rosenquist R., Gaidano G., Dyer M.J., Söderkvist P., Linderholm M., Oscier D., Tvaruzkova Z., Pospisilova S., Dührsen U., Greil R., Döhner H., Stilgenbauer S., Zenz T., European Research Initiative on CLL (ERIC):  MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica 99 (8) 1285-1291, 2014.

Bochtler T., Hegenbart U., Kunz C., Benner A., Seckinger A., Dietrich S., Granzow M., Neben K., Goldschmidt H., Ho A.D., Hose D., Jauch A., Schönland S.O.:  Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 21 (1) 9-17, 2014.

Brocks D., Assenov Y., Minner S., Bogatyrova O., Simon R., Koop C., Oakes C., Zucknick M., Lipka D.B., Weischenfeldt J., Feuerbach L., Cowper-Sal Lari R., Lupien M., Brors B., Korbel J., Schlomm T., Tanay A., Sauter G., Gerhäuser C., Plass C., ICGC Early Onset Prostate Cancer Project:  Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 8 (3) 798-806, 2014.

Claus R., Lucas D.M., Ruppert A.S., Williams K.E., Weng D., Patterson K., Zucknick M., Oakes C.C., Rassenti L.Z., Greaves A.W., Geyer S., Wierda W.G., Brown J.R., Gribben J.G., Barrientos J.C., Rai K.R., Kay N.E., Kipps T.J., Shields P., Zhao W., Grever M.R., Plass C., Byrd J.C.:  Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 124 (1) 42-48, 2014.

Dreidax D., Bannert S., Henrich K.O., Schröder C., Bender S., Oakes C.C., Lindner S., Schulte J.H., Duffy D., Schwarzl T., Saadati M., Ehemann V., Benner A., Pfister S., Fischer M., Westermann F.:  p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Hum.Mol.Genet. 23 (25) 6826-6837, 2014.

Dutruel C., Bergmann F., Rooman I., Zucknick M., Weichenhan D., Geiselhart L., Kaffenberger T., Rachakonda P.S., Bauer A., Giese N., Hong C., Xie H., Costello J.F., Hoheisel J., Kumar R., Rehli M., Schirmacher P., Werner J., Plass C., Popanda O., Schmezer P.:  Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Oncogene 33 3401-3410, 2014.

Edler L., Hart A., Greaves P., Carthew P., Coulet M., Boobis A., Williams G.M., Smith B.:  Selection of appropriate tumour data sets for Benchmark dose modelling (BMD) and derivation of a margin of exposure (MoE) for substances that are genotoxic and carcinogenic: consderations of biological relevance of tumour type, data quality and uncertainty assessment. Food Chem.Toxicol. 70 264-289, 2014.

Fabian J., Lodrini M., Öhme I., Schier M.C., Thole T.M., Hielscher T., Kopp-Schneider A., Opitz L., Capper D., Deimling A.v., Wiegand I., Milde T., Mahlknecht U., Westermann F., Popanda O., Röls F., Hero B., Berthold F., Fischer M., Kulozik A., Witt O., Deubzer H.E.:  GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res. 74 2604-2616, 2014.

Goeppert B., Konermann C., Schmidt C.R., Bogatyrova O., Geiselhart L., Ernst C., Gu L., Becker N., Zucknick M., Mehrabi A., Hafezi M., Klauschen F., Stenzinger A., Warth A., Breuhahn K., Renner M., Weichert W., Schirmacher P., Plass C., Weichenhan D.:  Global alterations of DNA methylation in cholangiocarcinoma targets the Wnt signaling pathway. Hepatol. 59 (2) 544-554, 2014.

Habl G., Hatiboglu G., Edler L., Uhl M., Krause S., Röthke M., Schlemmer H.P., Hadaschik B., Debus J., Herfarth K.:  Ion prostate irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. BMC Cancer 14 202, 2014.

Herth I., Dietrich S., Benner A., Hegenbart U., Rieger M., Stadtherr P., Bondong A., Tran T.H., Weide R., Hensel M., Knauf W., Franz-Werner J., Weislau M., Procaccianti M., Görner M., Meissner J., Luft T., Schönland S., Witzens-Harig M., Zenz T., Ho A.D., Dreger P.:  The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann.Oncol. 25 (1) 200-206, 2014.

Hillengass J., Weber M.A., Kilk K., Listl K., Wagner-Gund B., Hillengass M., Hielscher T., Farid A., Neben K., Delorme S., Landgren O., Goldschmidt H.:  Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukem. 28 174-178, 2014.

Holland-Letz T., Kopp-Schneider A.:  Optimal experimental designs for dose-response studies with continuous endpoints. Arch.Toxicol. (epub) , 2014.

Jiang X., Kopp-Schneider A.:  Statistical strategies for averaging EC50 from multiple dose-response experiments. Arch.Toxicol. (epub) , 2014.

Jiang X., Kopp-Schneider A.:  Summarizing EC50 estimates from multiple dose-response experiments: A comparison of a meta-analysis strategy to a mixed-effects model approach. Biometr.J. 56 (3) 493-512, 2014.

Kahlert C., Pecqueux M., Halama N., Dienemann H., Muley T., Pfannschmidt J., Lasitschka F., Klupp F., Schmidt T., Rahbari N., Reissfelder C., Kunz C., Benner A., Falk C., Weitz J., Koch M.:  Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. Br.J.Cancer 110 441-449, 2014.

Katayama S., Habl G., Kessel K., Edler L., Debus J., Herfarth K., Sterzing F.:  Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 trial. BMC Cancer 14 20, 2014.

Kloth J.K., Hillengass J., Listl K., Kilk K., Hielscher T., Landgren O., Delorme S., Goldschmidt H., Kauczor H.U., Weber M.A.:  Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Int.J.Cancer 135 2380-2386, 2014.

Körber S., Slynko A., Häfner M.F., Krug D., Schoneweg C., Kessel K., Kopp-Schneider A., Herfarth K., Debus J., Sterzing F.:  Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis. Radiat.Oncol. 9 (1) 113, 2014.

Körber S.A., Schoneweg C., Slynko A., Krug D., Häfner M.F., Herfarth K., Debus J., Sterzing F., Knebel-Doeberitz M.v., Prigge E.S., Reuschenbach M.:  Influence of human papillomavirus and p16INK4a on treatment outcome of patients with anal cancer. Radiat.Oncol. 113 (3) 331-336, 2014.

Kuhmann C., Li C., Kloor M., Salou M., Weigel C., Schmidt C.R., Ng L.W., Tsui W.W., Leung S.Y., Yuen S.T., Becker N., Weichenhan D., Plass C., Schmezer P., Chan T.L., Popanda O.:  Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer. Hum.Mol.Genet. 23 (8) 2043-2054, 2014.

Kunz C., Kieser M.:  Blinded versus unblinded covariate selection in confirmatory survival trials. J.Biopharm.Stat. 24 (2) 398-414, 2014.

Lacroix J., Schlund F., Leuchs B., Adolph K., Sturm D., Bender S., Hielscher T., Pfister S.M., Witt O., Rommelaere J., Schlehofer J.R., Witt H.:  Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int.J.Cancer 134 (3) 703-716, 2014.

Löffler H., Puthenparambil J., Hielscher T., Neben K., Krämer A.:  Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Dtsch.Arztebl.Int. 111 (27-28) 481-487, 2014.

Mack S.C., Witt H., Piro R.M., Gu L., Zuyderduyn S., Stütz A.M., Wang X., Gallo M., Garzia L., Zayne K., Zhang X., Ramaswamy V., Jäger N., Jones D.T., Sill M., Pugh T.J., Ryzhova M., Wani K.M., Shih D.J., Head R., Remke M., Bailey S.D., Zichner T., Faria C.C., Barszczyk M., Stark S., Seker-Cin H., Hutter S., Johann P., Bender S., Hovestadt V., Tzaridis T., Dubuc A.M., Northcott P.A., Peacock J., Bertrand K.C., Agnihotri S., Cavalli F.M., Clarke I., Nethery-Brokx K., Creasy C.L., Verma S.K., Koster J., Wu X., Yao Y., Milde T., Sin-Chan P., Zuccaro J., Lau L., Pereira S., Castelo-Branco P., Hirst M., Marra M.A., Roberts S.S., Fults D., Massimi L., Cho Y.J., Van Meter T., Grajkowska W., Lach B., Kulozik A.E., Deimling A.v., Witt O., Scherrer S.W., Fan X., Muraszko K.M., Kool M., Pomeroy S.L., Gupta N., Phillips J., Huang A., Tabori U., Hawkins C., Malkin D., Kongkham P.N., Weiss W.A., Jabado N., Rutka J.T., Bouffet E., Korbel J.O., Lupien M., Aldape K.D., Bader G.D., Eils R., Lichter P., Dirks P.B., Pfister S.M., Korshunov A., Taylor M.D.:  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 (7489) 445-450, 2014.

Madhavan D., Wallwiener M., Bents K., Zucknick M., Nees J., Schott S., Cuk K., Riethdorf S., Trumpp A., Pantel K., Sohn C., Schneeweiss A., Surowy H., Burwinkel B.:  Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res.Treat. 146 (1) 163-174, 2014.

Martins V.C., Busch K., Juraeva D., Blum C., Ludwig C., Rasche V., Lasitschka F., Mastitsky S.E., Brors B., Hielscher T., Fehling H.J., Rodewald H.R.:  Cell competition is a tumour suppressor mechanism in the thymus. Nature 509 465-470, 2014.

Meissner J., Tichy D., Dietrich S., Schmitt T., Ziepert M., Kuhnt E., Rixecker T., Witzens-Harig M., Pfreundschuh M., Ho A.D.:  Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br.J.Haematol. 166 (4) 612-615, 2014.

Merz M., Neben K., Raab M.S., Sauer S., Egerer G., Hundemer M., Hose D., Kunz C., Heiss C., Ho A.D., Goldschmidt H., Hillengass J.:  Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann.Oncol. 25 (1) 189-195, 2014.

Merz M., Hielscher T., Wagner B., Sauer S., Shah S., Raab M.S., Jauch A., Neben K., Hose D., Egerer G., Weber M.A., Delorme S., Goldschmidt H., Hillengass J.:  Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukem. 28 1902-1908, 2014.

Noack J., Choi J., Richter K., Kopp-Schneider A., Regnier-Vigouroux A.:  A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis. 5 e1425, 2014.

Oakes C.C., Claus R., Gu L., Assenov Y., Hüllein J., Zucknick M., Brocks D., Bogatyrova O., Schmidt C., Rassenti L., Kipps T.J., Mertens D., Lichter P., Döhner H., Stilgenbauer S., Byrd J.C., Zenz T., Plass C.:  Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4 348-361, 2014.

Pötsch A.R., Lipka D.B., Witte T., Claus R., Nöllke P., Zucknick M., Olk-Batz C., Fluhr S., Dworzak M., De Moerloose B., Stary J., Zecca M., Hasle H., Schmugge M., van den Heuvel-Eibrink M.M., Locatelli F., Niemeyer C.M., Flotho C., Plass C.:  RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics 9 (9) 1252-1260, 2014.

Röthke M.C., Kuru T.H., Schultze S., Tichy D., Kopp-Schneider A., Fenchel M., Schlemmer H.P., Hadaschik B.A.:  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur.Radiol. 24 (2) 344-352, 2014.

Saadati M., Benner A.:  Statistical challenges of high-dimensional methylation data. Stat.Med. 33 (30) 5347-5357, 2014.

Schlenk R.F., Kayser S., Bullinger L., Kobbe G., Casper J., Ringhoffer M., Held G., Brossart P., Lübbert M., Salih H.R., Kindler T., Horst H.A., Wulf G., Nachbaur D., Götze K., Lamparter A., Paschka P., Gaidzik V.I., Teleanu V., Späth D., Benner A., Krauter J., Ganser A., Döhner H., Döhner K., German Austrian AML Study Group:  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124 (23) 3441-3449, 2014.

Schrimpf D., Haag M., Pilz L.R.:  Possible combinations of electronic data capture and randomization systems. Principles and the realization with RANDI2 and OpenClinica. Meth.Inf.Med. 53 (3) 202-207, 2014.

Sill M., Hielscher T., Becker N., Zucknick M.:  c060: Extended inference with Lasso and elastic-net regularized Cox and generalized linear models. J.Statist.Software 62 (5) 1-22, 2014.

Sonnet M., Claus R., Becker N., Zucknick M., Petersen J., Lipka D.B., Oakes C.C., Andrulis M., Lier A., Milsom M.D., Witte T., Gu L., Kim-Wanner S.Z., Schirmacher P., Wulfert M., Gattermann N., Lübbert M., Rosenbauer F., Rehli M., Bullinger L., Weichenhan D., Plass C.:  Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Med. 6 (4) 34, 2014.

Srinivasan H., Allory Y., Sill M., Vordos D., Alhamdani M.S., Radvanyi F., Hoheisel J.D., Schröder C.:  Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. Proteomics 14 (11) 1333-1342, 2014.

Steinert G., Schölch S., Niemietz T., Iwata N., Garcia S.A., Behrens B., Voigt A., Kloor M., Benner A., Bork U., Rahbari N.N., Büchler M.W., Stöcklein N.H., Weitz J., Koch M.:  Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 74 (8) 1694-1704, 2014.

Uhl M., Edler L., Jensen A.D., Habl G., Oelmann J., Röder F., Jäckel A., Debus J., Herfarth K.:  Randomized phase II trial of hypofractionated proton versus carbon iron radiation therapy in patients with sacrococcygeal chordoma - the IASC trial protocol. Radiat.Oncol. 9 100, 2014.

Weber T.F., Müller T., Biesdorf A., Wörz S., Rengier F., Heye T., Holland-Letz T., Rohr K., Kauczor H.U., Tengg-Kobligk H.v.:  True four-dimensional analysis of thoracic aortic displacement and distension using model-based segmentation of computed tomography angiography. Int.J.Cardiovasc.Imaging 30 (1) 185-194, 2014.

Weiler M., Blaes J., Pusch S., Sahm F., Czabanka M., Luger S., Bunse L., Solecki G., Eichwald V., Jugold M., Hodecker S., Osswald M., Meisner C., Hielscher T., Rübmann P., Pfenning P.N., Ronellenfitsch M., Kempf T., Schnölzer M., Abdollahi A., Lang F., Bendszus M., Deimling A.v., Winkler F., Weller M., Vajkoczy P., Platten M., Wick W.:  mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. PNAS 111 (1) 409-414, 2014.

Weisser M., Yeh R.F., Duchateau-Nguyen G., Palermo G., Nguyen T.Q., Shi X., Stinson S.Y., Yu N., Dufour A., Robak T., Salogub G.N., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., Larratt L., Rossiev V.A., Bence-Bruckler I., Geisler C.H., Montillo M., Fischer K., Fink A.M., Hallek M., Blöhdorn J., Busch R., Benner A., Döhner H., Valente N., Wenger M.K., Stilgenbauer S., Dornan D.:  PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood 124 (3) 420-425, 2014.

Wielpütz M.O., Puderbach M., Kopp-Schneider A., Stahl M., Fritzsching E., Sommerburg O., Ley S., Sumkauskaite M., Biederer J., Kauczor H.U., Eichinger M., Mall M.A.:  Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am.J.Respir.Crit.Care Med. 189 (8) 956-965, 2014.

Wiestler B., Capper D., Hovestadt V., Sill M., Jones D.T., Hartmann C., Felsberg J., Platten M., Feiden W., Keyvani K., Pfister S.M., Wiestler O.D., Meyermann R., Reifenberger G., Pietsch M., von Deimling A., Weller M., Wick W.:  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncol. 16 (12) 1630-1638, 2014.

Wiestler B., Capper D., Sill M., Jones D.T., Hovestadt V., Sturm D., Koelsche C., Bertoni A., Schweizer L., Korshunov A., Weiss E.K., Schliesser M.G., Radbruch A., Herold-Mende C., Roth P., Unterberg A., Hartmann C., Pietsch T., Reifenberger G., Lichter P., Radlwimmer B., Platten M., Pfister S.M., von Deimling A., Weller M., Wick W.:  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 128 561-571, 2014.

to top
powered by webEdition CMS